Background. Parathyroidectomy offers the only cure for primary hyperparathyroidism, but today only 50% of primary hyperparathyroidism patients are referred for operation, in large part, because the condition is widely under-recognized. The diagnosis of primary hyperparathyroidism can be especially challenging with mild biochemical indices. Machine learning is a collection of methods in which computers build predictive algorithms based on labeled examples. With the aim of facilitating diagnosis, we tested the ability of machine learning to distinguish primary hyperparathyroidism from normal physiology using clinical and laboratory data. Methods. This retrospective cohort study used a labeled training set and 10-fold cross-validation to evaluate accuracy of the algorithm. Measures of accuracy included area under the receiver operating characteristic curve, precision (sensitivity), and positive and negative predictive value. Several different algorithms and ensembles of algorithms were tested using the Weka platform. Among 11,830 patients managed operatively at 3 high-volume endocrine surgery programs from March 2001 to August 2013, 6,777 underwent parathyroidectomy for confirmed primary hyperparathyroidism, and 5,053 control patients without primary hyperparathyroidism underwent thyroidectomy. Test-set accuracies for machine learning models were determined using 10-fold cross-validation. Age, sex, and serum levels of preoperative calcium, phosphate, parathyroid hormone, vitamin D, and creatinine were defined as potential predictors of primary hyperparathyroidism. Mild primary hyperparathyroidism was defined as primary hyperparathyroidism with normal preoperative calcium or parathyroid hormone levels. Results. After testing a variety of machine learning algorithms, Bayesian network models proved most accurate, classifying correctly 95.2% of all primary hyperparathyroidism patients (area under receiver operating characteristic = 0.989). Omitting parathyroid hormone from the model did not decrease the accuracy significantly (area under receiver operating characteristic = 0.985). In mild disease cases, however, the Bayesian network model classified correctly 71.1% of patients with normal calcium and 92.1% with normal parathyroid hormone levels preoperatively. Bayesian networking and AdaBoost improved the accuracy of all parathyroid hormone patients to 97.2% cases (area under receiver operating characteristic = 0.994), and 91.9% of primary hyperparathyroidism patients with mild disease. This was significantly improved relative to Bayesian networking alone (P < .0001). Conclusion. Machine learning can diagnose accurately primary hyperparathyroidism without human input even in mild disease. Incorporation of this tool into electronic medical record systems may aid in recognition of this under-diagnosed disorder. (Surgery 2017;161:1113-21.) 
nephrolithiasis, renal insufficiency, peptic ulcer disease, acid reflux, cardiovascular disease, and hypertension. Neurocognitive changes, like fatigue, depression, anxiety, memory loss, and irritability, also are associated with PHPT. [1] [2] [3] Operative excision of hyperfunctioning parathyroid glands is the only curative treatment for PHPT, often with >95% success rates. [4] [5] [6] Currently, however, less than half of biochemically proven PHPT patients are referred for parathyroidectomy. 7, 8 PHPT is the most common cause for increased serum levels of calcium in the ambulatory population, but documented hypercalcemia often exists for many years before PHPT is diagnosed formally and evaluated. [8] [9] [10] Numerous potential reasons could explain why a knowledgeable provider might delay or forgo further workup for PHPT. In one study of the electronic medical record (EMR) of a large health system, only 32% of patients with hypercalcemia had PTH measured, suggesting that underrecognition rather than conscious observation accounts for much of the undertreatment for PHPT. 8 The increasing availability of data through EMR systems offers a valuable opportunity to improve PHPT recognition. Federal incentives have led to the rapid proliferation of EMR systems, but the use of these tools to analyze the vast amounts of data contained within EMRs still lag behind their widespread adoption. 11, 12 Computer-based decision support tools have improved health care delivery in domains, including preventative care and drug interactions, [13] [14] [15] to guide clinical decision-making. Decision-support tools exist commonly as alerts to prompt or alter entry of physician orders. 16 Supervised methods of machine learning (ML) are focused on inferring predictive models from existing datasets that consist of labeled examples, 17, 18 and in clinical medicine, such methods can classify or predict future outcomes for a given patient. 19, 20 ML approaches have been used to predict risk of breast cancer from mammographic findings 21 or to risk stratify patients for venous thromboembolism from EMR data. 22 In this study, we hypothesized that ML could diagnose PHPT accurately based on readily available clinical and laboratory indicators. We describe the development and evaluation of a ML method that predicts PHPT accurately using a large, multi-institutional dataset. Improving recognition of the disease and distinguishing mild disease from normal variations drove the work described here.
METHODS
Study sample and definitions. The Institutional Review Boards of the University of Wisconsin School of Medicine and Public Health, the University of Pittsburgh School of Medicine, and the Medical College of Wisconsin approved the collection of data. We compiled a dataset from the existing, prospectively collected, perioperative datasets of 11,830 patients from 3 high-volume academic centers. Of these patients, 6,777 patients (study) with biochemical PHPT underwent an initial parathyroid operation for sporadic disease. Only patients confirmed to have PHPT at the time of operation were included in the study group. The remaining 5,053 patients (control) underwent thyroidectomy without parathyroid disease as determined by preoperative laboratory indices. The dates of operations spanned from March 2001 to August 2013. All patients undergoing parathyroidectomy were diagnosed preoperatively to have biochemical evidence of PHPT, and control patients did not have biochemical evidence of PHPT, because both groups had a minimum of serum calcium and PTH levels measured preoperatively.
ML is a collection of different methods or algorithms, each with differing mechanisms of classification. The typical approach for using ML for clinical problems is to test a variety of different algorithms to find the most accurate one. To accomplish this task, we used the ML software platform available from the Waikato Environment for Knowledge Analysis (version 3.6.11, Weka). The Weka software suite contains a library of algorithms that build predictive models by learning from examples provided in usersupplied datasets. Each algorithm was trained using our patient dataset, which included 7 attributes that we considered most likely to be relevant to PHPT diagnosis: age at operation, sex, and preoperative serum levels of calcium, paired preoperative PTH, 25-hydroxy vitamin D, creatinine, and phosphate. Predictor variables chosen for 2 reasons: 1) they were available consistently within the databases from the 3 institutions, and 2) represent initial, routinely available data within a given patient's EMR that could indicate PHPT without an exhaustive or complete workup for PHPT. The studied laboratory values were those obtained closest in time to the date of operation.
As outlined in the recent operative guidelines on management of hyperparathyroidism, 21 serum calcium and PTH levels vary quite characteristically a bit during the biochemical diagnosis of PHPT. In normocalcemic hyperparathyroidism, the serum calcium can be intermittently normal. Alternatively, the PTH level can fall within the normal range but still be inappropriately high for the serum calcium level. For the purposes of this study, "mild" PHTP was defined to be present when either the calcium or PTH level that was recorded closest to the operative date was within the normal range. 23 Correct diagnostic classification of mild PHPT was defined to be present when a patient's ML-predicted disease status agreed with his physicians' preoperative diagnostic impression based on biochemical indices.
Classification methods. We began by testing several categories of supervised ML classifiers: 1) rule-based classifiers, 2) logistic regression-based classifiers, 3) tree-based classifiers, and 4) Bayesian network classifiers. After testing >20 different algorithms, we selected the Bayesian Network (BayesNet) for additional study as it maximized accuracy and transparency. A Bayesian Network uses a graphic representation to represent a compact encoding of the joint distribution of input variables and the outcome(s) of interest. 24, 25 Although more complex Bayesian network structures were evaluated, the na€ ıve Bayes models proved as accurate and more comprehensible than the complex networks. A na€ ıve Bayesian network is one in which the graph structure posits that each input variable is independent of the others when conditioned on the outcome variable. The BayesNet method handles missing data through a process called imputation, where missing features are inferred from other cases where those features are present. Therefore, the algorithm does not require complete datasets for either training or prediction. 26 We then explored means to improve the accuracy of the diagnostic model for patients with mild biochemical disease. The method selected is known as adaptive boosting or AdaBoost, a metaalgorithm that can be coupled with other classifiers to improve performance 27 by placing more weight on previously misclassified instances, thereby "boosting" previously weak classifiers. AdaBoost was chosen to place more weight on the misclassified, mild biochemical cases. An ensemble of BayesNet in conjunction with AdaBoost was then run on the established datasets.
Statistical analysis. All ML classifiers were tested using 10-fold cross validation. The performance of each classifier was evaluated based on sensitivity (recall), specificity, positive predictive value (precision), area under the receiver operating characteristic (ROC) curve, and overall accuracy. Continuous variables are represented by their mean ± standard deviation. Statistical comparisons of continuous variables were made using Student t test. Categorical variables were statistically compared using Pearson v 2 test. Data are presented as mean ± standard error of the mean.
RESULTS
Baseline patient characteristics and accuracy of Bayesian network-based model. This sample study included 6,777 biochemically confirmed PHPT patients and 5,053 control patients, of whom 76.5% and 80.1% were female, respectively. PHPT patients (age, 59 ± 1 year) were older than control patients (age, 49 ± 1 year; P < .0001). Serum levels of calcium, PTH, phosphate, vitamin D, and creatinine were all consistent with the biochemical definition of PHPT (Table I) . 23 In the study, 8,450 cases had at least 1 missing feature, but 79.1% of the cases had only 1 missing feature. The most common missing features in descending order were phosphate, creatinine, and vitamin D.
After testing a variety of ML methods, we found that a na€ ıve Bayesian network predicted most accurately patient diagnoses (PHPT versus control). A graphic representation of the network structure is shown in Fig, with each feature contributing independently to the probabilistic classification of patients. Here, the Bayesian network is "na€ ıve," because each feature is conditionally dependent on the outcome alone without any arcs or probabilistic relationships between the predictor features. The Bayesian networks resulted in a test set accuracy of 95.2%, and an area under the ROC curve of 0.989 (Table II) .
Patients with mild biochemical indices for PHPT represent a diagnostic challenge, because they must be distinguished from those with secondary causes of increased serum PTH such as vitamin D deficiency. Hence, we further tested the accuracy of our model in making diagnostic predictions that were consistent with our specialists' clinical diagnoses specifically in these subpopulations (Table II) . The accuracy of our model did not change for patients with low serum levels of vitamin D (<30 ng/mL), classifying correctly 95.6%. Among patients with mild biochemical disease (N = 1,738); however, we observed a decrease in the accuracy of classification to 86.0%. These findings suggest that the accuracy of the BayesNet predictive model may be more limited when it comes to categorizing patients with milder biochemical disease.
We investigated further all the misclassified PHPT cases and compared them with the correctly classified instances. When we compared PHPT patients who were diagnosed correctly (true positives) with those mistaken as normal (false negatives), the latter group was on average younger, had greater serum phosphate levels (P < .001), and had greater serum vitamin D levels (P = .0002 each). Much of the misclassification occurred in mild biochemical disease; 99% of the false negatives had mild disease, while only 23% of the true positives had mild disease. False negatives had a serum calcium level within normal range (9.7 ± 0.1 mg/dL) and a much lesser mean serum PTH level (110.9 ± 10.6 pg/mL) compared with that of true positives (181.0 ± 7.1 pg/mL, P < .001).
Control patients who were classified correctly (true negatives) were on average younger than those classified incorrectly as having PHPT (false positives; P < .001). The false positive controls exhibited greater mean calcium (10.1 ± 0.1 mg/dL), and PTH levels (74.1 ± 4.2 pg/mL; P < .001). Of Associated with each node is a conditional probability distribution that represents the distribution of the node variable conditioned on its parents in the graph. In this case, the model is a "na€ ıve" Bayesian network, meaning that each input feature is treated as being independent of the others when conditioned on the outcome variable (PHPT or normal). the control patients, 6.3% were mistaken to have PHPT.
Adaptive boosting of BayesNet. Although the BayesNet algorithm alone was highly accurate, this ML tool becomes even more useful to experts if it can distinguish reliably those cases of mild hyperparathyroidism. To decrease the rate of misclassification among the mild cases, we used the meta-algorithm known as adaptive boosting in conjunction with BayesNet; we observed that doing so enhanced our model's classification accuracy from 95.2-97.2% with an area under the ROC of 0.994 (Table III) . The total number of misclassified patients decreased from 563 (4.76%) using BayesNet alone, to 329 (2.78%) using the BayesNet and AdaBoost model (Table III) . Because many of the previously misclassified patients had mild PHPT, the use of adaptive boosting improved the accuracy of classification among those with mild disease.
With the same patient dataset used for the original BayesNet model, we again compared the biochemical profiles of those misclassified to those classified correctly after BayesNet and AdaBoost. The boosted model decreased the number of false negatives from 246 (2.07%) to 149 (1.26%, P < .0001, Table III ). Importantly, AdaBoost decreased the number of false negatives with mild disease (14.0% in BayesNet alone compared with 8.1% in BayesNet and AdaBoost, P < .0001, Table III ). The improvement in classification of mild cases was associated with a small increase in false positives in the control group, specifically for patients with serum PTH levels greater than the upper limit of normal (2.7% vs 3.6% false positives, P < .0001).
Alternative ML approach. Because the observed accuracy of the BayesNet and AdaBoost was greater than in many clinical studies using methods of ML, 22, 28 we sought to test its classification accuracy using an alternate approach. Rather than using 10-fold cross-validation (randomly chosen test sets), we used each institutional data as a separate test set allowing assessment of any institutional variations in accuracy that may indicate different referral or diagnosis patterns. The model was trained in the UW dataset and then tested on the other 2 institutional datasets. Although there were slight differences in sensitivity and specificity, the Bayesian network had similar overall accuracy when tested in this way, and the area under the ROC curve was nearly identical to our original analysis (Table IV) .
Omission of PTH. The set of laboratory values included as predictive features for the above BayesNet and boosted algorithm included a serum PTH level. For clinicians to order a serum PTH level, however, means they already are considering the diagnosis of PHPT. To assist physicians who lacks awareness of PHPT or are not yet considering that particular diagnosis, we also tested several ML models omitting PTH as a predictive feature. Again, BayesNet proved the most accurate algorithm, classifying correctly 95.6% of all study cases. The false positive rate was 5.4%, and the area under the ROC curve was 0.985. Meta-algorithms like adaptive boosting could not improve the accuracy of the BayesNet alone in this particular setting.
DISCUSSION
In summary, we trained a ML algorithm to diagnose PHPT based on biochemical and demographic data using a multi-institutional dataset. The algorithm was highly accurate, with greater than 95% accuracy tested by 2 different techniques. The boosted algorithm performed remarkably well even for patients with mild disease. Additionally, the boosted algorithm seemed to be useful in distinguishing mild hyperparathyroidism from normal, physiologic alterations in serum calcium and/or PTH. The BayesNet model without PTH remained highly accurate even without PTH as a predictive feature. Therefore, we provide different algorithms useful in different scenarios, depending on the informational needs of the provider: the BayesNet and AdaBoost is useful for the expert trying to distinguish mild disease from normal physiology, while the BayesNet without serum PTH can assist the clinician who lacks diagnostic conviction and/or awareness of the disease. Either or both algorithms could serve as the underlying code for a support tool for clinical decision making that prompts physicians to refer patients for further evaluation when labs are consistent with PHPT.
The clinical diagnosis of PHPT is based primarily on interpretation of laboratory indices, including serum levels of PTH, calcium and vitamin D. 29, 30 Emerging evidence indicates that many patients with biochemical evidence of this disease remain undiagnosed, resulting in a vast, unrecognized population of afflicted patients. 7, 8 Within the Kaiser health care system (3.5 million patients), more than half of those with biochemical evidence of PHPT did not undergo a parathyroidectomy during a 13-year period, regardless of symptoms or fulfillment of international consensus criteria for treatment. 7 Such population level studies, however, cannot indicate why patients go untreated. Several other studies had similar findings: for patients with increased serum calcium, unfortunately serum PTH levels frequently are not obtained despite PHPT being the most common cause of outpatient hypercalcemia. [7] [8] [9] [10] To address situations where serum PTH is never ordered, we tested ML algorithms without PTH as a predictive feature and found BayesNet without PTH is still greater than 95% sensitive for detecting PHPT.
Even for patients who meet objective diagnostic criteria, several studies have found that parathyroidectomy is underutilized, 8, 31 and the undertreatment seems to hinge on at least 2 factors: first, a lack of diagnostic awareness, and second, deferment of evaluation. 32 The informatics tools reported here can assist with recognition, and the integration of such tools into the EMR can prompt timely referral for further evaluation and treatment. Importantly, this tool utilizes readily available clinical data and provides automated diagnosis without additional cost or invasive testing.
Parathyroidectomy benefits PHPT patients by not only correcting their biochemical disease, but also by preventing the progression of PHPT-related complications, including worsening bone mineral density and fragility fractures. [33] [34] [35] [36] Compared with observation, Almqvist et al 37 determined that early parathyroidectomy decreased the patients' longterm risk of hip and other bone fractures. Longstanding PHPT also has been associated with poorer quality of life, psychiatric illnesses, left ventricular hypertrophy, and an increased mortality risk from cardiovascular disease. [38] [39] [40] [41] [42] [43] [44] [45] Additionally, parathyroidectomy is more cost-effective than observation. 46 The ML tool developed here may aid both practitioners and patients to recognize and treat the disease earlier to decrease longterm morbidity.
It is important to identify mild PHPT, because patients without substantial biochemical disease still experience symptoms and a decrease in bone density. 47, 48 Accumulating studies provide evidence that mild PHPT patients benefit from parathyroidectomy despite not meeting formal consensus criteria for operative intervention 23, 33, 34, 42, 47, 49, 50 as the new AAES operative guidelines discuss in detail. 21 Moreover, the incidence of mild PHPT is increasing. 51 Diagnosis of mild biochemical PHPT becomes challenging for primary providers, endocrinologists, and surgeons. Aside from difficulty distinguishing the mild biochemical PHPT from normal physiology or secondary causes of hyperparathyroidism, the symptoms associated with PHPT are often nonspecific. Symptoms like fatigue or musculoskeletal pain are common in PHPT and numerous other conditions. 7-9,52 Therefore, physicians may focus on other causes of reported symptoms prior to evaluating increased serum calcium or PTH fully. Adaptive boosting of the Bayesian classifier improved the classification mild PHPT, and in doing so, increased the overall accuracy of the model. For clinicians with less awareness of PHPT, the model without serum PTH can prompt further workup. For instance, a "pop-up" alert might prompt the provider to order a serum PTH. Hence, this tool can aid both the expert and the nonspecialist to distinguish PHPT from normal variants, or at least prompt earlier biochemical evaluation by raising awareness for clinicians less familiar with PHPT.
Emerging computer decision-support tools that use ML assist physicians reliably in a variety of other domains, such as predicting venous thromboembolism, assessing breast cancer risk, or detection of myocardial infarction. 21, 22, 28, 53 But, few decision-support aids for diagnosing PHPT exist currently and are limited mainly to graphic representations of where abnormal calcium and PTH values intersect in standard laboratory reporting. These graphs use arbitrary cutoffs, whereas the Bayesian Network utilized in this study was trained on nearly 12,000 examples of normal and abnormal patient laboratory results.
The tool described here uses readily available clinical data to alert the provider automatically when his or her patient exhibits certain laboratory features of PHPT, thereby prompting further evaluation or referral. Such automated alerts can become incorporated into existing EMR systems as "best practices alerts." Clinical decision-making is a complex task requiring the physician to integrate multiple pieces of diverse data types, synthesize all this information, and bridge the "inferential gap" between the data at hand and the clinical knowledge needed to make the correct diagnosis or treatment decision. 54, 55 Computerized decisionsupport tools overcome many of these challenges and can improve the quality of care through prompts or second opinions in real-time at the point of care. The other advantage of incorporating ML algorithms into EMRs is the ability to improve continuously with the addition of more data. Hence, our Bayesian Network to recognize PHPT could become even more accurate as it is "trained" on more patients. Clinicians rarely work with complete data sets. Because our classification method displayed excellent accuracy despite the high frequency of missing features, we expect it to maintain its accuracy in real-world, clinical settings.
Limitations. The present study is limited by its retrospective nature; we tried to address this with the large, multi-institutional sample used to train our classifier and, in addition, we used 3 different institutions to investigate for any institutional biases. The study patients also comprised only those referred for parathyroidectomy which introduces a potential selection bias, because our sample could represent those with a more severe presentation that prompted the physicians to recommend operation rather than continued observation. A third potential limitation is the determination of test-set accuracies by crossvalidation within the dataset, thus making it difficult to predict how the algorithms would perform in a different population, although the model was observed to have similar overall accuracy when evaluated across 3 institutions. The study group only included patients from operative databases diagnosed confidently with PHPT. Future testing of the tool should include those patients being observed or worked up further for PHPT. Hence, the methods described here will require prospective testing in different patient populations prior to robust clinical implementation. Another potential flaw was our decision to use in just one set of biochemical indices taken at the time point close to operation, which was a practical decision for evaluation of the huge masses of laboratory data in this pilot study. Future analysis of this tool should include laboratory values taken at multiple time points to reflect actual clinical practice which may potentially increase the accuracy for the most challenging cases. Finally, because this is an operative cohort, most patients affected with urinary calcium leak or familial hypocalciuric hypercalcemia were not included, so there is no way to determine here how well the algorithm would perform on these uniquely challenging cases. Due to the geographic location of the three examined centers and the case mix of their controls, the training set did include many patients with vitamin D deficiency and hyperthyroidism, which are 2 common secondary causes of increases in PTH. 21 
